Q4 2024 Earnings Call Transcript March 27, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.29, ...

Reflecting the growing global demand for seamless multilingual communication, Iris Production, a leading provider of hybrid and virtual event production, has announced a strategic partnership with ...

The SATURN NITRO is PIC32MK development board that closely follows the Arduino Nano form factor, but with much beefier specs ...

Taal’s lawsuit, filed with fellow Cornell doctoral student Sriram Parasuram and Mukoma Wa Ngũgĩ, a Cornell literature ...

Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company" or "Dominari") today announced its preliminary, unaudited revenue results for the full year ended December 31, 2024.

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

"Zentalis reported significant progress in the development of azenosertib in 2024 and made important advancements this year. We plan to maintain strong execution on the late-stage development of ...

Agree Realty's disciplined investment strategy and robust balance sheet, with no major debt until 2028. Read why ADC stock is ...

New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected ...

OS Therapies ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness, CEO, and Gerald ...

MGC026, which is a TOP1i-based ADC, is undergoing a phase 1 dose-escalation study in patients with advanced solid tumors. The ...